Clear All
11564 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
51144-0002-12 51144-0002 Tucatinib TUKYSA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor HER2 Oral Apr 17, 2020 In Use
50242-0145-01 50242-0145 Pertuzumab Perjeta 30.0 mg/mL Immunotherapy Monoclonal Antibody HER2 Intravenous Jun 8, 2012 In Use
74527-0022-02 74527-0022 margetuximab-cmkb MARGENZA 25.0 mg/mL Immunotherapy Monoclonal Antibody HER2 Intravenous Jan 15, 2021 In Use
69448-0016-11 69448-0016 Trastuzumab-strf HERCESSI 420.0 mg/20mL Immunotherapy Monoclonal Antibody HER2 Intravenous Jan 1, 2025 In Use
00069-0308-01 00069-0308 trastuzumab-qyyp Trazimera 150.0 mg/7.15mL Immunotherapy Monoclonal Antibody HER2 Intravenous Mar 10, 2021 In Use
50242-0260-01 50242-0260 Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Phesgo 20000.0 U/10mL, 600.0 mg/10mL, 600.0 mg/10mL Immunotherapy Monoclonal Antibody HER2 Subcutaneous Jun 29, 2020 In Use
68727-0950-02 68727-0950 Zanidatamab-hrii ZIIHERA 50.0 mg/mL Immunotherapy Bispecific Antibody HER2 Intravenous Nov 20, 2024 In Use
50242-0132-10 50242-0132 Trastuzumab Herceptin 150.0 mg/7.4mL Immunotherapy Monoclonal Antibody HER2 Intravenous Jun 3, 2019 In Use
50242-0260-86 50242-0260 Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Phesgo 20000.0 U/10mL, 600.0 mg/10mL, 600.0 mg/10mL Immunotherapy Monoclonal Antibody HER2 Subcutaneous May 3, 2021 In Use
83257-0004-12 83257-0004 Trastuzumab-dkst OGIVRI Immunotherapy Monoclonal Antibody HER2 Oct 1, 2023 In Use
74527-0022-03 74527-0022 margetuximab-cmkb MARGENZA 25.0 mg/mL Immunotherapy Monoclonal Antibody HER2 Intravenous Jan 15, 2021 In Use
50242-0333-01 50242-0333 Trastuzumab Herceptin Immunotherapy Monoclonal Antibody HER2 Feb 10, 2017 Feb 10, 2017 No Longer Used
83257-0003-01 83257-0003 Trastuzumab-dkst, Trastuzumab OGIVRI 420.0 mg/20mL Immunotherapy Monoclonal Antibody HER2 Intravenous Oct 1, 2023 In Use
50242-0088-01 50242-0088 ADO-Trastuzumab Emtansine Kadcyla 20.0 mg/mL, 20.0 mg/mL Immunotherapy Drug Antibody Conjugate HER2 Intravenous Feb 22, 2013 In Use
00006-5034-02 00006-5034 Ontruzant Ontruzant Immunotherapy Monoclonal Antibody HER2 Intravenous Apr 15, 2020 Sep 30, 2023 No Longer Used
50242-0132-01 50242-0132 Trastuzumab Herceptin 150.0 mg/7.4mL Immunotherapy Monoclonal Antibody HER2 Intravenous Feb 10, 2017 In Use
55513-0141-01 55513-0141 trastuzumab-anns Kanjinti 150.0 mg/7.15mL Immunotherapy Monoclonal Antibody HER2 Intravenous Oct 28, 2019 In Use
83257-0001-11 83257-0001 Trastuzumab-dkst OGIVRI 150.0 mg/7.4mL Immunotherapy Monoclonal Antibody HER2 Intravenous Oct 1, 2023 In Use
83077-0100-02 83077-0100 Zenocutuzumab BIZENGRI 20.0 mg/mL Immunotherapy Bispecific Antibody HER2, HER3 Intravenous Dec 4, 2024 In Use
71837-1000-02 71837-1000 Zenocutuzumab BIZENGRI 20.0 mg/mL Immunotherapy Bispecific Antibody HER2, HER3 Intravenous Dec 16, 2024 In Use
00006-5331-59 00006-5331 Belzutifan WELIREG 40.0 mg/1 Chemotherapy Miscellaneous Agent HIF-2 alpha Oral Jun 21, 2023 In Use
00006-5331-58 00006-5331 Belzutifan WELIREG 40.0 mg/1 Chemotherapy Miscellaneous Agent HIF-2 alpha Oral Jun 21, 2023 In Use
00006-5331-01 00006-5331 Belzutifan WELIREG 40.0 mg/1 Chemotherapy Miscellaneous Agent HIF-2 alpha Oral Aug 13, 2021 In Use
80446-0401-01 80446-0401 TEBENTAFUSP KIMMTRAK 100.0 ug/.5mL Immunotherapy T Cell Receptor (TCR) HLA-A*02:01 Intravenous Jan 26, 2022 In Use
52125-0833-01 52125-0833 Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant GARDASIL Ancillary Therapy Protective Agent HPV Vaccine Intramuscular Feb 13, 2014 Feb 11, 2015 No Longer Used

Found 11564 results — Export these results